Neurocrine Biosciences, Inc.
As of Oct 22, 2026, Neurocrine Biosciences is in Stage 3, the topping phase, now in week 8 (since Aug 28, 2026). It closed at $143.29, 22.8% below its 52-week high and below its 200-day average, which is falling.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is NBIX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
NBIX among Drug Manufacturers - Specialty & Generic30th of 84 by relative strength
All 84 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CPIX | Stage 2 · wk 23 | 98 | +6.8% |
| 2 | ETON | Stage 2 · wk 30 | 97 | −10.1% |
| 3 | ANIK | Stage 2 · wk 15 | 96 | +3.5% |
| 4 | IRWD | Stage 3 · wk 3 | 96 | −16.4% |
| 5 | TEVA | Stage 2 · wk 9 | 95 | +3.1% |
| 6 | AMRX | Stage 2 · wk 19 | 95 | +5.9% |
| 7 | KNSA | Stage 2 · wk 73 | 95 | +6.2% |
| 8 | AMLX | Stage 2 · wk 15 | 93 | −6.6% |
| …30 | NBIX | Stage 3 · wk 8 | 54 | +2.7% |
Neurocrine Biosciences: quick answers
What stage is Neurocrine Biosciences in?
As of Oct 22, 2026, Neurocrine Biosciences (NBIX) is in Stage 3, the topping phase. It entered Stage 3 on Aug 28, 2026 and is in week 8. What the four stages mean
Is Neurocrine Biosciences in an uptrend?
Its uptrend has stalled. Neurocrine Biosciences is in Stage 3, the topping phase that follows an advance. It trades 2.6% below its 200-day average, which is falling.
How far is Neurocrine Biosciences from its 52-week high?
Neurocrine Biosciences closed at $143.29 on Oct 22, 2026, 22.8% below its 52-week high of $185.50. Its 52-week low is $123.10.
How has Neurocrine Biosciences performed over the past year?
As of Oct 22, 2026, Neurocrine Biosciences is up 0.4% over the past year and up 1.9% so far in 2026.
Which sector and industry is Neurocrine Biosciences in?
Neurocrine Biosciences is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - Specialty & Generic
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.